APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuromyelitis Optica Drug

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

Selected research

Market Outlook & Growth Opportunities

Global Neuromyelitis Optica Drug Market Outlook and Growth Opportunities 2026

9 January 2026197 pages

Choose your research edition.

Industry ResearchNeuromyelitis Optica Drug Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuromyelitis Optica Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Neuromyelitis Optica Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuromyelitis Optica Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuromyelitis Optica Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

Read the full market overview

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

This report provides an overview of the global Neuromyelitis Optica Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuromyelitis Optica Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuromyelitis Optica Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neuromyelitis Optica Drug market.

Neuromyelitis Optica Drug Segment by Company

Pfizer

Fresenius

Teva

Sandoz

Intas

Gyjtrs

NANG KUANG

Tianjin Kingyork

Baxter

CSL

Grifols

Octapharma

CBOP

Neuromyelitis Optica Drug Segment by Type

Glucocorticoids

Immunotherapies

Others

Neuromyelitis Optica Drug Segment by Application

Acute Attack

Remission Prophylactic Treatment

Neuromyelitis Optica Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neuromyelitis Optica Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neuromyelitis Optica Drug key companies, revenue, market share, and recent developments.

3. To split the Neuromyelitis Optica Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neuromyelitis Optica Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuromyelitis Optica Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Neuromyelitis Optica Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuromyelitis Optica Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuromyelitis Optica Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuromyelitis Optica Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuromyelitis Optica Drug industry.

Chapter 3: Detailed analysis of Neuromyelitis Optica Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neuromyelitis Optica Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neuromyelitis Optica Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuromyelitis Optica Drug Industry Trends Table 2. Neuromyelitis Optica Drug Industry Drivers Table 3. Neuromyelitis Optica Drug Industry Opportunities and Challenges Table 4. Neuromyelitis Optica Drug Industry Restraints Table 5. Global Neuromyelitis Optica Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuromyelitis Optica Drug Revenue Share by Company (2021-2026) Table 7. Global Neuromyelitis Optica Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neuromyelitis Optica Drug Key Company Manufacturing Base & Headquarters Table 9. Global Neuromyelitis Optica Drug Company, Product Type & Application Table 10. Global Neuromyelitis Optica Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neuromyelitis Optica Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Glucocorticoids Table 15. Significant Companies of Immunotherapies Table 16. Significant Companies of Others Table 17. Global Neuromyelitis Optica Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Neuromyelitis Optica Drug Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Neuromyelitis Optica Drug Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Neuromyelitis Optica Drug Sales Value Share by Type (2021-2026) Table 21. Global Neuromyelitis Optica Drug Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Acute Attack Table 23. Significant Companies of Remission Prophylactic Treatment Table 24. Global Neuromyelitis Optica Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Neuromyelitis Optica Drug Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Neuromyelitis Optica Drug Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Neuromyelitis Optica Drug Sales Value Share by Application (2021-2026) Table 28. Global Neuromyelitis Optica Drug Sales Value Share by Application (2027-2032) Table 29. Global Neuromyelitis Optica Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Neuromyelitis Optica Drug Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Neuromyelitis Optica Drug Sales Value Share by Region (2021-2026) Table 32. Global Neuromyelitis Optica Drug Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Neuromyelitis Optica Drug Sales Value Share by Region (2027-2032) Table 34. Global Neuromyelitis Optica Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Neuromyelitis Optica Drug Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Neuromyelitis Optica Drug Sales Value Market Share by Country (2021-2026) Table 37. Global Neuromyelitis Optica Drug Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Neuromyelitis Optica Drug Sales Value Market Share by Country (2027-2032) Table 39. Pfizer Company Information Table 40. Pfizer Business Overview Table 41. Pfizer Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Pfizer Neuromyelitis Optica Drug Product Portfolio Table 43. Pfizer Recent Development Table 44. Fresenius Company Information Table 45. Fresenius Business Overview Table 46. Fresenius Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Fresenius Neuromyelitis Optica Drug Product Portfolio Table 48. Fresenius Recent Development Table 49. Teva Company Information Table 50. Teva Business Overview Table 51. Teva Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Teva Neuromyelitis Optica Drug Product Portfolio Table 53. Teva Recent Development Table 54. Sandoz Company Information Table 55. Sandoz Business Overview Table 56. Sandoz Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Sandoz Neuromyelitis Optica Drug Product Portfolio Table 58. Sandoz Recent Development Table 59. Intas Company Information Table 60. Intas Business Overview Table 61. Intas Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Intas Neuromyelitis Optica Drug Product Portfolio Table 63. Intas Recent Development Table 64. Gyjtrs Company Information Table 65. Gyjtrs Business Overview Table 66. Gyjtrs Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Gyjtrs Neuromyelitis Optica Drug Product Portfolio Table 68. Gyjtrs Recent Development Table 69. NANG KUANG Company Information Table 70. NANG KUANG Business Overview Table 71. NANG KUANG Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. NANG KUANG Neuromyelitis Optica Drug Product Portfolio Table 73. NANG KUANG Recent Development Table 74. Tianjin Kingyork Company Information Table 75. Tianjin Kingyork Business Overview Table 76. Tianjin Kingyork Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Tianjin Kingyork Neuromyelitis Optica Drug Product Portfolio Table 78. Tianjin Kingyork Recent Development Table 79. Baxter Company Information Table 80. Baxter Business Overview Table 81. Baxter Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Baxter Neuromyelitis Optica Drug Product Portfolio Table 83. Baxter Recent Development Table 84. CSL Company Information Table 85. CSL Business Overview Table 86. CSL Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. CSL Neuromyelitis Optica Drug Product Portfolio Table 88. CSL Recent Development Table 89. Grifols Company Information Table 90. Grifols Business Overview Table 91. Grifols Neuromyelitis Optica Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 92. Grifols Neuromyelitis Optica Drug Product Portfolio Table 93. Grifols Recent Development Table 94. Octapharma Company Information Table 95. Octapharma Business Overview Table 96. Octapharma Neuromyelitis Optica Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 97. Octapharma Neuromyelitis Optica Drug Product Portfolio Table 98. Octapharma Recent Development Table 99. CBOP Company Information Table 100. CBOP Business Overview Table 101. CBOP Neuromyelitis Optica Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 102. CBOP Neuromyelitis Optica Drug Product Portfolio Table 103. CBOP Recent Development Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Neuromyelitis Optica Drug Product Image Figure 2. Global Neuromyelitis Optica Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuromyelitis Optica Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Glucocorticoids Image Figure 8. Immunotherapies Image Figure 9. Others Image Figure 10. Global Neuromyelitis Optica Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Neuromyelitis Optica Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Neuromyelitis Optica Drug Sales Value Share by Type (2021-2032) Figure 13. Acute Attack Image Figure 14. Remission Prophylactic Treatment Image Figure 15. Global Neuromyelitis Optica Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Neuromyelitis Optica Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Neuromyelitis Optica Drug Sales Value Share by Application (2021-2032) Figure 18. Global Neuromyelitis Optica Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Neuromyelitis Optica Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Neuromyelitis Optica Drug Sales Value (2021-2032) & (US$ Million) Figure 21. North America Neuromyelitis Optica Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Neuromyelitis Optica Drug Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Neuromyelitis Optica Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Neuromyelitis Optica Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Neuromyelitis Optica Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Neuromyelitis Optica Drug Sales Value (2021-2032) & (US$ Million) Figure 27. South America Neuromyelitis Optica Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Neuromyelitis Optica Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Neuromyelitis Optica Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Glucocorticoids
  • Immunotherapies
  • Others
Applications
  • Acute Attack
  • Remission Prophylactic Treatment
Companies covered
  • Pfizer
  • Fresenius
  • Teva
  • Sandoz
  • Intas
  • Gyjtrs
  • NANG KUANG
  • Tianjin Kingyork
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • CBOP

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neuromyelitis Optica Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neuromyelitis Optica Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neuromyelitis Optica Drug Market Dynamics
  1. 2.1 Neuromyelitis Optica Drug Industry Trends
  2. 2.2 Neuromyelitis Optica Drug Industry Drivers
  3. 2.3 Neuromyelitis Optica Drug Industry Opportunities and Challenges
  4. 2.4 Neuromyelitis Optica Drug Industry Restraints
3 Neuromyelitis Optica Drug Market by Company
  1. 3.1 Global Neuromyelitis Optica Drug Company Revenue Ranking in 2025
  2. 3.2 Global Neuromyelitis Optica Drug Revenue by Company (2021-2026)
  3. 3.3 Global Neuromyelitis Optica Drug Company Ranking (2024-2026)
  4. 3.4 Global Neuromyelitis Optica Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Neuromyelitis Optica Drug Company Product Type and Application
  6. 3.6 Global Neuromyelitis Optica Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neuromyelitis Optica Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neuromyelitis Optica Drug Market by Type
  1. 4.1 Neuromyelitis Optica Drug Type Introduction
  2. 4.1.1 Glucocorticoids
  3. 4.1.2 Immunotherapies
  4. 4.1.3 Others
  5. 4.2 Global Neuromyelitis Optica Drug Sales Value by Type
  6. 4.2.1 Global Neuromyelitis Optica Drug Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neuromyelitis Optica Drug Sales Value by Type (2021-2032)
  8. 4.2.3 Global Neuromyelitis Optica Drug Sales Value Share by Type (2021-2032)
5 Neuromyelitis Optica Drug Market by Application
  1. 5.1 Neuromyelitis Optica Drug Application Introduction
  2. 5.1.1 Acute Attack
  3. 5.1.2 Remission Prophylactic Treatment
  4. 5.2 Global Neuromyelitis Optica Drug Sales Value by Application
  5. 5.2.1 Global Neuromyelitis Optica Drug Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Neuromyelitis Optica Drug Sales Value by Application (2021-2032)
  7. 5.2.3 Global Neuromyelitis Optica Drug Sales Value Share by Application (2021-2032)
6 Neuromyelitis Optica Drug Regional Value Analysis
  1. 6.1 Global Neuromyelitis Optica Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuromyelitis Optica Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neuromyelitis Optica Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neuromyelitis Optica Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neuromyelitis Optica Drug Sales Value (2021-2032)
  7. 6.3.2 North America Neuromyelitis Optica Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neuromyelitis Optica Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Neuromyelitis Optica Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neuromyelitis Optica Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neuromyelitis Optica Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neuromyelitis Optica Drug Sales Value (2021-2032)
  16. 6.6.2 South America Neuromyelitis Optica Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neuromyelitis Optica Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neuromyelitis Optica Drug Sales Value Share by Country, 2025 VS 2032
7 Neuromyelitis Optica Drug Country-level Value Analysis
  1. 7.1 Global Neuromyelitis Optica Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuromyelitis Optica Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neuromyelitis Optica Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neuromyelitis Optica Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neuromyelitis Optica Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neuromyelitis Optica Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neuromyelitis Optica Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Neuromyelitis Optica Drug Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Fresenius
  8. 8.2.1 Fresenius Company Information
  9. 8.2.2 Fresenius Business Overview
  10. 8.2.3 Fresenius Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Fresenius Neuromyelitis Optica Drug Product Portfolio
  12. 8.2.5 Fresenius Recent Developments
  13. 8.3 Teva
  14. 8.3.1 Teva Company Information
  15. 8.3.2 Teva Business Overview
  16. 8.3.3 Teva Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva Neuromyelitis Optica Drug Product Portfolio
  18. 8.3.5 Teva Recent Developments
  19. 8.4 Sandoz
  20. 8.4.1 Sandoz Company Information
  21. 8.4.2 Sandoz Business Overview
  22. 8.4.3 Sandoz Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sandoz Neuromyelitis Optica Drug Product Portfolio
  24. 8.4.5 Sandoz Recent Developments
  25. 8.5 Intas
  26. 8.5.1 Intas Company Information
  27. 8.5.2 Intas Business Overview
  28. 8.5.3 Intas Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Intas Neuromyelitis Optica Drug Product Portfolio
  30. 8.5.5 Intas Recent Developments
  31. 8.6 Gyjtrs
  32. 8.6.1 Gyjtrs Company Information
  33. 8.6.2 Gyjtrs Business Overview
  34. 8.6.3 Gyjtrs Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Gyjtrs Neuromyelitis Optica Drug Product Portfolio
  36. 8.6.5 Gyjtrs Recent Developments
  37. 8.7 NANG KUANG
  38. 8.7.1 NANG KUANG Company Information
  39. 8.7.2 NANG KUANG Business Overview
  40. 8.7.3 NANG KUANG Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 NANG KUANG Neuromyelitis Optica Drug Product Portfolio
  42. 8.7.5 NANG KUANG Recent Developments
  43. 8.8 Tianjin Kingyork
  44. 8.8.1 Tianjin Kingyork Company Information
  45. 8.8.2 Tianjin Kingyork Business Overview
  46. 8.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Product Portfolio
  48. 8.8.5 Tianjin Kingyork Recent Developments
  49. 8.9 Baxter
  50. 8.9.1 Baxter Company Information
  51. 8.9.2 Baxter Business Overview
  52. 8.9.3 Baxter Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Baxter Neuromyelitis Optica Drug Product Portfolio
  54. 8.9.5 Baxter Recent Developments
  55. 8.10 CSL
  56. 8.10.1 CSL Company Information
  57. 8.10.2 CSL Business Overview
  58. 8.10.3 CSL Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 CSL Neuromyelitis Optica Drug Product Portfolio
  60. 8.10.5 CSL Recent Developments
  61. 8.11 Grifols
  62. 8.11.1 Grifols Company Information
  63. 8.11.2 Grifols Business Overview
  64. 8.11.3 Grifols Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Grifols Neuromyelitis Optica Drug Product Portfolio
  66. 8.11.5 Grifols Recent Developments
  67. 8.12 Octapharma
  68. 8.12.1 Octapharma Company Information
  69. 8.12.2 Octapharma Business Overview
  70. 8.12.3 Octapharma Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Octapharma Neuromyelitis Optica Drug Product Portfolio
  72. 8.12.5 Octapharma Recent Developments
  73. 8.13 CBOP
  74. 8.13.1 CBOP Company Information
  75. 8.13.2 CBOP Business Overview
  76. 8.13.3 CBOP Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 CBOP Neuromyelitis Optica Drug Product Portfolio
  78. 8.13.5 CBOP Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst